RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc. (RVP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Operations are based in Little Elm, Texas, with significant manufacturing reliance on Chinese suppliers (57.6% of units in the first six months of 2026). The Company operates in a single reportable segment.

Key Financial Metrics

Note: Net income for the three months ended June 30, 2026, was driven primarily by a $6.37 million realized gain on the sale of equity securities and $1.47 million in Technology Investment Agreement (TIA) income, offsetting a significant operating loss.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 31.1% year-over-year for the three months ended June 30, 2026 ($7.20M vs. $10.45M) and 23.3% for the six-month period ($14.38M vs. $18.74M). The decline is attributed to decreased unit sales of EasyPoint needles and timing of customer orders.
• Operating Performance: Operating loss widened to $11.31 million for the six months ended June 30, 2026, compared to $9.81 million in the prior year period. This was driven by lower revenue and a 10% increase in operating expenses, partly due to non-recurring charitable product donations ($0.96M) and consultant fees ($0.42M).
• Investment Activity: The Company recorded a $6.37 million realized gain on the sale of equity securities in the second quarter of 2026, a non-recurring item not present in the prior year's comparable period.
• Workforce Reduction: In April 2026, the Company reduced its workforce by approximately 16%, expected to save $2.2 million annually in wages and benefits.

Outlook, Risks, and Management Commentary

• Tariff Impact: The Company faces significant headwinds from tariffs on Chinese imports. As of August 1, 2026, the prevailing tariff rate on syringe and needle products from China is 112.5% (100% Section 301 tariff + 12.5% new Section 301 tariff). Management is mitigating this by increasing domestic production of 1mL, 3mL, and EasyPoint needles and adapting equipment for 0.5mL syringes.
• Liquidity: Management believes it has adequate means to meet short-term needs for at least 12 months using cash reserves and liquidation of investments ($37.2M). However, liquidity is expected to decline materially over the next 1-3 years due to increased costs from tariffs and domestic manufacturing transitions.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses previously reported. Remediation efforts are ongoing.
• Contingencies: The Company holds a $1.3 million liability for tariff refunds received that were processed incorrectly and may be subject to repayment. Additionally, $4.0 million is accrued for estimated contractual pricing allowances (rebates).

Investor Verification Checklist

• Sustainability of Earnings: Verify the extent to which the Q2 2026 net income is dependent on the one-time $6.37M investment gain versus core operating performance.
• Tariff Mitigation: Assess the timeline and success of the transition to domestic manufacturing for 0.5mL syringes and the ability to absorb the 112.5% tariff on remaining Chinese imports.
• Liquidity Runway: Confirm the Company's ability to fund operations for the next 12-24 months given the projected decline in liquidity and high fixed costs from the Technology Investment Agreement (TIA).
• Internal Control Remediation: Monitor progress on fixing the material weaknesses in internal controls over financial reporting to ensure future financial statement reliability.
• Customer Concentration: Note that 48.1% of six-month sales came from just two significant customers; verify the stability of these relationships.